Virtual Screening Yields Inhibitors of Novel Antifungal Drug Target, Benzoate 4-Monooxygenase

Fungal CYP53 enzymes are highly conserved proteins, involved in phenolic detoxification, and have no homologues in higher eukaryotes, rendering them favorable drug targets. Aiming to discover novel CYP53 inhibitors, we employed two parallel virtual screening protocols and evaluated highest scoring hit compounds by analyzing the spectral binding interactions, by surveying the antifungal activity, and assessing the inhibition of catalytic activity. On the basis of combined results, we selected 3-methyl-4-(1H-pyrrol-1-yl)benzoic acid (compound 2) as the best candidate for hit-to-lead follow-up in the antifungal drug discovery process.

[1]  Nada Krasevec,et al.  High diversity and complex evolution of fungal cytochrome P450 reductase: cytochrome P450 systems. , 2008, Fungal genetics and biology : FG & B.

[2]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[3]  Andrew W Munro,et al.  Crystal Structure of the Mycobacterium tuberculosis P450 CYP121-Fluconazole Complex Reveals New Azole Drug-P450 Binding Mode* , 2006, Journal of Biological Chemistry.

[4]  J. Maertens,et al.  History of the development of azole derivatives. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  Brian K Shoichet,et al.  Interpreting steep dose-response curves in early inhibitor discovery. , 2006, Journal of medicinal chemistry.

[6]  Arturo Casadevall,et al.  An insight into the antifungal pipeline: selected new molecules and beyond , 2010, Nature Reviews Drug Discovery.

[7]  C. Jefcoate,et al.  Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. , 1978, Methods in enzymology.

[8]  Matej Praprotnik,et al.  ENZO: A Web Tool for Derivation and Evaluation of Kinetic Models of Enzyme Catalyzed Reactions , 2011, PloS one.

[9]  Anna Tramontano,et al.  The PMDB Protein Model Database , 2005, Nucleic Acids Res..

[10]  Y Yoshida,et al.  Studies on the substrate-induced spectral change of cytochrome P-450 in liver microsomes. , 1975, Journal of biochemistry.

[11]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[12]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[13]  P. Gubbins,et al.  Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450 , 2011, Expert opinion on drug metabolism & toxicology.

[14]  P. Carver,et al.  Comparison of echinocandin antifungals , 2007, Therapeutics and clinical risk management.

[15]  F Peter Guengerich,et al.  Function of human cytochrome P450s: characterization of the orphans. , 2005, Biochemical and biophysical research communications.

[16]  Chris Oostenbrink,et al.  Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450 , 2008 .

[17]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[18]  S. Orrenius,et al.  The nature of the reverse type I (modified type II) spectral change in liver microsomes. , 1972, Biochemistry.

[19]  Chris Oostenbrink,et al.  Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. , 2008, Expert opinion on drug metabolism & toxicology.

[20]  V. Shandas,et al.  Valuing ecological systems and services , 2011, F1000 biology reports.

[21]  M. Pfaller,et al.  Epidemiology of Invasive Mycoses in North America , 2010, Critical reviews in microbiology.

[22]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[23]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[24]  Tal Pupko,et al.  ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids , 2010, Nucleic Acids Res..

[25]  Tania C Sorrell,et al.  Antifungal therapy in invasive fungal infections. , 2010, Current opinion in pharmacology.

[26]  J. Perfect,et al.  Azoles: back to the future , 2011 .

[27]  Matthias Rarey,et al.  Feature trees: A new molecular similarity measure based on tree matching , 1998, J. Comput. Aided Mol. Des..

[28]  S. Orrenius,et al.  A study of the modified type II spectral change produced by the interaction of agroclavine with cytochrome P-450. , 1972, Biochimica et biophysica acta.

[29]  C. Rotstein,et al.  Emerging fungal infections in immunocompromised patients , 2011, F1000 medicine reports.

[30]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[31]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[32]  Chris Oostenbrink,et al.  Cytochrome P450 3A4 Inhibition by Ketoconazole: Tackling the Problem of Ligand Cooperativity Using Molecular Dynamics Simulations and Free-Energy Calculations , 2012, J. Chem. Inf. Model..

[33]  Hiroshi Yamazaki,et al.  Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. , 2009, Chemical research in toxicology.

[34]  P. Ortiz de Montellano,et al.  Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1. , 2011, Bioorganic & medicinal chemistry letters.

[35]  I. Schuster,et al.  Inhibition of Cytochromes P450: Existing and New Promising Therapeutic Targets , 2007, Drug metabolism reviews.

[36]  A. Kashuba,et al.  Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion , 2011 .

[37]  S. Sligar,et al.  Substrate interaction with cytochrome P-450. , 1981, Pharmacology & therapeutics.

[38]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[39]  K. Ang,et al.  Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit , 2009, PLoS neglected tropical diseases.

[40]  D. V. Slyke,et al.  THE MODE OF ACTION OF UREASE AND OF ENZYMES IN GENERAL , 1914 .

[41]  F Peter Guengerich,et al.  Three-dimensional Structure of Steroid 21-Hydroxylase (Cytochrome P450 21A2) with Two Substrates Reveals Locations of Disease-associated Variants* , 2012, The Journal of Biological Chemistry.

[42]  Andrew Howard,et al.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam , 1993 .

[43]  Andriy Kryshtafovych,et al.  Protein Model Database , 2005 .

[44]  D W Nebert,et al.  Correlation of type I, type II, and reverse type I difference spectra with absolute changes in spin state of hepatic microsomal cytochrome P-450 iron from five mammalian species. , 1978, The Journal of biological chemistry.

[45]  Matthew P. Jacobson,et al.  A Nonazole CYP51 Inhibitor Cures Chagas’ Disease in a Mouse Model of Acute Infection , 2010, Antimicrobial Agents and Chemotherapy.

[46]  J. Perfect,et al.  Use of Antifungal Combination Therapy: Agents, Order, and Timing , 2010, Current fungal infection reports.

[47]  K. Nakamura,et al.  Cytochrome P450rm from Rhodotorula minuta catalyzes 4-hydroxylation of benzoate. , 1996, Journal of biochemistry.

[48]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[49]  A Srinivas Reddy,et al.  Virtual screening in drug discovery -- a computational perspective. , 2007, Current protein & peptide science.

[50]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[51]  R. Estabrook,et al.  Spectral studies of drug interaction with hepatic microsomal cytochrome. , 1967, Molecular pharmacology.

[52]  J. Duine,et al.  Purification and characterization of benzoate-para-hydroxylase, a cytochrome P450 (CYP53A1), from Aspergillus niger. , 2001, Archives of biochemistry and biophysics.

[53]  T. Poulos,et al.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. , 1987, Biochemistry.

[54]  Samuel A. Lee,et al.  Emerging moulds: epidemiological trends and antifungal resistance , 2011, Mycoses.

[55]  A. Kashuba,et al.  Mechanisms of Drug Interactions I , 2005 .

[56]  Jure Stojan,et al.  CYP53A15 of Cochliobolus lunatus, a target for natural antifungal compounds. , 2008, Journal of medicinal chemistry.